MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Cardiovascular
  • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts
    • MPR: Breakthrough Products Series
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Job Board
    • Leadership in Medtech
    • Manufacturer Search
    • Videos
    • Whitepapers
  • DeviceTalks
You are here: Home / Legal News / Legal: Becton appeals $114M antitrust loss to Retractable Technologies

Legal: Becton appeals $114M antitrust loss to Retractable Technologies

October 17, 2013 By Arezu Sarvestani Leave a Comment

Becton hopes to reverse $114M Retractable Technologies antitrust win

As promised, Becton Dickinson & Co. (NYSE:BDX) filed an appeal, hoping to overturn a $113.5 million legal loss to long-time rival Retractable Technologies (NYSE:RVP).

Becton asked a Texas court to reconsider the lawsuit on the grounds that RTI’s attorneys "failed to present sufficient evidence" to support the ruling, handed down last month, that BD violated the Lanham Act’s false advertising proscription.

A jury in September ruled in favor of Retractable Technologies, finding that BD used deception to monopolize the market for safety syringes. The jury awarded RTI a little more than $13.5 million for "deception regarding safety syringes," according to court documents.

BD asked the court to reconsider the ruling, given that the jury rejected all of RTI’s claims of "anticompetitive contracting" and ruled only that BD engaged in attempted monopolization. BD maintained that it is entitled to judgment as a matter of law on the matter of monopolization and that further argued that RTI had failed to produce substantial evidence that BD had engaged in "exclusionary" conduct.

"Even if false advertising, disparagement or patent infringement could in theory constitute exclusionary conduct, far more than harm to a competitor (like RTI) would be necessary to establish that the conduct posed a ‘significant and enduring adverse impact to competition itself’," BD said in legal filings. "There is no substantial evidence to show that BD’s advertising, disparagement (‘tainting’), or patent infringement threatened to destroy competition itself in the safety syringe market."

BD had vowed last month to appeal RTI’s win, saying that the company was "disappointed" with a verdict it deemed "erroneous." The case has dragged on for some 6 years, with patent infringement accusations stemming back to 2007,  when Retractable sued on allegations that Becton’s Integra syringes infringe patents covering its competing VanishPoint devices.

Filed Under: Legal News, News Well Tagged With: Anti-Trust, becton dickinson, Retractable Technologies Inc.

In case you missed it

  • Medtronic faces patent lawsuit over CoreValve tech
  • Orpyx launches sensory insoles with patient monitoring
  • Ortho devicemakers Hensler and Tobra face off in patent lawsuit
  • House bill asks CMS to cover breakthrough devices for Medicare patients
  • Empirical Spine completes enrollment in LimiFlex pivotal trial
  • MolecuLight wins FDA clearance for handheld imaging device
  • Medical device tax will cost 20,000 jobs, report says
  • W.L. Gore officials think they can spur insulin delivery system innovation
  • EPA moves closer to stricter regulations on medtech ethylene oxide sterilization
  • 3DBio Therapeutics wins FDA rare pediatric disease designation for outer ear reconstruction
  • CryoLife wins CE Mark for E-nya thoracic stent graft
  • Edwards projects $5 billion in sales for 2020
  • SPR Therapeutics announces 1000th placement of nerve stimulation device
  • The best places to work for medtech sales reps
  • DePuy Synthes issues urgent field safety notice for USS II Polyaxial 3D heads
  • Haemonetics (HAE) launches SafeTrace Tx in North America
  • Vicarious Surgical wins FDA breakthrough designation for surgical robot

RSS From Medical Design & Outsourcing

Leave a Reply Cancel reply

You must be logged in to post a comment.

Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Popular Posts

  • Report: SEC probes GE Healthcare, Philips, Siemens in Chinese bribery scheme
  • Edwards Lifesciences warns against below-market mini-tender offer Edwards Lifesciences
  • J&J’s Ethicon files ITC complaint against Intuitive Surgical Intuitive Surgical's EndoWrist instruments
  • Auris Health loses motion to move Intuitive Surgical patent suit from Del. to Cali. Johnson & Johnson's Auris, Intuitive Surgical
  • Enable Injections inks deal with Sanofi for drug delivery platform enfuse-enable-injections
Tweets by @MassDevice
MDO ad

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion

MASSDEVICE

Subscribe to MassDevice
Advertise with us
About
Contact us
Add us on FacebookMassDevice Network
Follow us on Twitter@MassDevice
Connect with us on LinkedInLinkedIn
Follow us on YouTube YouTube

Copyright © 2019 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS